Biogen

Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR Clinical Trials Arena07:25Biotechnology Pharma Biotech

X-Elio inks VPPAs with Cisco, Biogen, others for 172 MW of US solar RenewablesNow.com12:07Cisco Solar Power Renewable Energy

Biogen initiates phase 3 study of felzartamab in kidney transplant patients PMLiVE08:26Pharma Biotech

Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacks Clinical Trials Arena07:06Alzheimer's Eli Lilly Pharma

Swiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and Biogen did the same ENDPOINTS11:10Alzheimer's Biotech Switzerland

Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia Pharmaceutical Technology07:22Canada Pharma Biotech

Leqembi enters second consultation period following NICE draft guidance update PharmaTimes05:13Alzheimer's Pharma Biotech

Stoke CEO Ed Kaye to depart shortly after inking Biogen pact and before its first Phase 3 trial ENDPOINTS10:44Pharma Biotech

How is biogen's stock performance compared to other biotech stocks? Barchart06:06Biotechnology Pharma Healthcare

NICE agrees to look again at Alzheimer's drug Leqembi pharmaphorum07:04Alzheimer's Pharma Biotech

Latest News

In the last 7 days

After Securing Biogen Pact, Stoke’s CEO Edward Kaye Bows Out Scrip Pharma Intelligence12:54 19-Mar-25

How Is Biogen's Stock Performance Compared to Other Biotech Stocks? Barchart06:06 19-Mar-25

Stoke CEO Ed Kaye to depart shortly after inking Biogen pact and before its first Phase 3 trial ENDPOINTS10:44 18-Mar-25

Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia Pharmaceutical Technology07:22 18-Mar-25

In the last month

Stock Shake-Up: ON Semiconductor, General Dynamics, Digital Turbine, Biogen, Cleveland-Cliffs TipRanks09:06 15-Mar-25

Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall? Zacks09:00 14-Mar-25

Biogen initiates phase 3 study of felzartamab in kidney transplant patients PMLiVE08:26 13-Mar-25

X-Elio inks VPPAs with Cisco, Biogen, others for 172 MW of US solar RenewablesNow.com12:07 12-Mar-25

X-ELIO closes six US PPAs with Cisco, Biogen, IDEXX, and Waters Corporation PR Newswire (Press Release)09:06 12-Mar-25

Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR Clinical Trials Arena07:25 12-Mar-25

Biogen to Participate in the Stifel 2025 Virtual CNS Forum Biogen (Press Release)16:22 11-Mar-25

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney… GlobeNewswire (Press Release)07:31 11-Mar-25

Biogen, Apple study finds smart devices can track cognition pharmaphorum04:46 7-Mar-25

Gene Therapy Market Global Forecast to 2032: Biopharma Giants Lead Gene Therapy Market Expansion – Latest Developments… GlobeNewswire (Press Release)04:15 7-Mar-25

In UK, it's strike 2 for Alzheimer's treatments from Lilly and Biogen/Eisai FiercePharma11:25 6-Mar-25

NICE agrees to look again at Alzheimer's drug Leqembi pharmaphorum07:04 6-Mar-25

Leqembi enters second consultation period following NICE draft guidance update PharmaTimes05:13 6-Mar-25

Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacks Clinical Trials Arena07:06 5-Mar-25

Swiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and Biogen did the same ENDPOINTS11:10 4-Mar-25

Leqembi Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight GlobeNewswire (Press Release)13:03 3-Mar-25

Australia stands firm on 'no' to Alzheimer's drug Leqembi pharmaphorum08:03 3-Mar-25

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia Biogen (Press Release)02:53 3-Mar-25

Eisai, Biogen's Leqembi emerges from safety reappraisal unscathed as Europe's CHMP endorses… FiercePharma10:42 28-Feb-25

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s … Biogen (Press Release)08:07 28-Feb-25

Biogen to Participate in the Leerink Global Healthcare Conference 2025 Biogen (Press Release)16:11 27-Feb-25

Biogen to Participate in the TD Cowen 45th Annual Health Care Conference Biogen (Press Release)16:12 24-Feb-25

Biogen Stock Outlook: Is Wall Street Bullish or Bearish? Barchart08:11 24-Feb-25

Biogen Options Trading: A Deep Dive into Market Sentiment Nasdaq14:02 21-Feb-25

Biogen gains rights to Stoke’s Dravet syndrome candidate in deal worth $550m PMLiVE07:39 20-Feb-25

view more headlines

19 Mar 12:54

About our Biogen News

Biogen is an American multinational biotechnology company that specialises in treatment of neurological diseases.

Publication filters

Sorry, no headlines or news topics were found. Please try different keywords.